Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors
Science Advances · 04.07.2025 · 11 (27)
DOI: 10.1126/sciadv.adx4562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 04.07.2025. Verfasst von Anna Pellattiero und 11 weiteren Autor:innen. Beteiligte Einrichtung: Veneto Institute of Molecular Medicine, Via Orus 2, 35129 Padova, Italy. Hauptthemen laut MEDLINE: GTP Phosphohydrolases, Cytochromes c, Proto-Oncogene Proteins c-bcl-2, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
The guanosine triphosphatase (GTPase) activity of the mitochondrial dynamin-related protein Optic Atrophy 1 (OPA1) regulates cristae remodeling, cytochrome c release, and apoptosis. Elevated OPA1 levels in multiple cancers correlate with reduced therapy sensitivity and poor survival, calling for specific OPA1 GTPase inhibitors. A high-throughput screening of ~10,000 compounds identified MYLS22, a heterocyclic N -pyrazole derivative as a reversible, noncompetitive OPA1 GTPase inhibitor. MYLS22 engaged with OPA1 in vitro and in cells where it induced cristae remodeling and mitochondrial fragmentation contingent on intactness of its predicted OPA1 binding site. MYLS22 enhanced proapoptotic cytochrome c release and sensitized breast adenocarcinoma cells to anti–Bcl-2 therapy, without toxicity on noncancer cells. By MYLS22 structure-activity relationship studies, we obtained Opa1 inhibitor 0 (Opitor-0) that inhibited OPA1, promoted cytochrome c release, and restored anti–Bcl-2 therapy sensitivity more efficiently than MYLS22. These chemical probes validate OPA1 as a therapeutic target to increase cancer cell apoptosis at the mitochondrial level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Veneto Institute of Molecular Medicine, Via Orus 2, 35129 Padova, Italy.
- Department of Biology, University of Padova, Via U. Bassi 58B, 35121 Padova, Italy.
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
- Molecular Modeling Section, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
- Departments of Biochemistry and Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
ORCID-Profile: Anna Pellattiero, Federico Magrin, Mattia Sturlese, Alberto Fracasso, Nikolaos Biris, Laura Cendron, Evripidis Gavathiotis, Stefano Moro, Andrea Mattarei, Luca Scorrano
Förderung
- NCI NIH HHS
Zitieren
APA
Pellattiero, A., Quirin, C., Magrin, F., Sturlese, M., Fracasso, A., Biris, N., Herkenne, S., Cendron, L., Gavathiotis, E., Moro, S., Mattarei, A., & Scorrano, L. (2025). Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors. Science Advances, 11(27). https://doi.org/10.1126/sciadv.adx4562
Vancouver
Pellattiero A, Quirin C, Magrin F, Sturlese M, Fracasso A, Biris N, et al. Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors. Science Advances. 2025;11(27). doi:10.1126/sciadv.adx4562
BibTeX
@article{Pellattiero2025,
author = {Pellattiero, Anna and Quirin, Charlotte and Magrin, Federico and Sturlese, Mattia and Fracasso, Alberto and Biris, Nikolaos and Herkenne, Stéphanie and Cendron, Laura and Gavathiotis, Evripidis and Moro, Stefano and Mattarei, Andrea and Scorrano, Luca},
title = {Small molecule OPA1 inhibitors amplify cytochrome c release and reverse cancer cells resistance to Bcl-2 inhibitors},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {27},
doi = {10.1126/sciadv.adx4562}
}
EUVIMED